2019 year-end financial report: Sites opened for recruitment to the pivotal Phase III study SPARKLE
Ascelia Pharma AB (publ) (ticker: ACE) today published its year-end report for the period July 2019 – December 2019, which is now available on the company’s website (the financial year will going forward follow the calendar year): https://www.ascelia.com/tag/reports-presentations/SIGNIFICANT EVENTS IN THE PERIOD · Julie Waras Brogren appointed as Chief Commercial Officer · Detailed preparations ahead of the start of the Phase III study SPARKLE with Mangoral · Four sites opened for patient enrollment in December and one additional site opened in January 2020 for the SPARKLE study